Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACLX-001
- Development stage
- Unknown
- Lead developer
- Arcellx
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
ACLX-001 is an investigational, adaptive cell therapy developed by Arcellx for the treatment of relapsed or refractory multiple myeloma. It is composed of ARC-T cells and a bivalent SparX protein that targets B-cell maturation antigen (BCMA), utilizing the same antigen-binding domain as anitocabtagene autoleucel. The therapy leverages the ARC-SparX platform, which allows controllable and adaptable CAR-T cell activity through soluble protein adapters, enabling activation or silencing in vivo in a dose-dependent manner. The mechanism involves immunologic cytotoxicity mediated by engineered T lymphocytes directed against BCMA-expressing myeloma cells[1][2][3][4][5][6][7].
- Other names
- ARC-T/sparX-BCMA
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on ACLX-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACLX-001.